Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemia.
Pediatrics-General Pediatrics
Therapy of childhood acute lymphoblastic leukemia in resource-poor geospaces.
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
See All 7 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020 08 07; 10(8):81.
View in:
PubMed
subject areas
Acute Disease
Adult
Antineoplastic Agents, Immunological
Bone Marrow
Humans
Kaplan-Meier Estimate
Middle Aged
Neoplasm Recurrence, Local
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognosis
Treatment Outcome
authors with profiles
Wendy Stock